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OBJECTIVE We investigated the prognostic impact of 24-h blood pressure control in treated hypertensive
subjects.
BACKGROUND There is growing evidence that ambulatory blood pressure improves risk stratification in
untreated subjects with essential hypertension. Surprisingly, little is known on the prognostic
value of this procedure in treated subjects.
METHODS Diagnostic procedures including 24-h noninvasive ambulatory blood pressure monitoring
were undertaken in 790 subjects with essential hypertension (mean age 48 years) before
therapy and after an average follow-up of 3.7 years (2,891 patient-years).
RESULTS At the follow-up visit, 26.6% of subjects achieved adequate office blood pressure control
(140/90 mm Hg), and 37.3% of subjects achieved adequate ambulatory blood pressure
control (daytime blood pressure135/85 mm Hg). Months or years after the follow-up visit,
58 patients suffered a first cardiovascular event. Event rate was lower (0.71 events/100
person-years) among the subjects with adequate ambulatory blood pressure control than
among those with higher blood pressure levels (1.87 events/100 person-years) (p  0.0026).
Ambulatory blood pressure control predicted a lesser risk for subsequent cardiovascular
disease independently of other individual risk factors (RR 0.36; 95% confidence intervals: 0.18
to 0.70; p  0.003), including age, diabetes and left ventricular hypertrophy. Office blood
pressure control was associated with a nonsignificant lesser risk of subsequent events (RR
0.63; 95% confidence intervals: 0.31 to 1.31; p  NS). In-treatment ambulatory blood
pressure was more potent than pre-treatment blood pressure for prediction of subsequent
cardiovascular disease.
CONCLUSIONS Ambulatory blood pressure control is superior to office blood pressure control for prediction
of individual cardiovascular risk in treated hypertensive subjects. (J Am Coll Cardiol 2002;
39:878–85) © 2002 by the American College of Cardiology Foundation
Despite the awareness of the elevated cardiovascular risk
associated with hypertension (1) and the availability of
effective and well-tolerated antihypertensive drugs, only a
minority of treated hypertensive subjects achieve adequate
blood pressure (BP) control (2–4). Clinical studies indicate
that many subjects with elevated BP are not treated aggres-
sively by their doctors (3) and that long-term compliance
with therapy may be poor (5). Lack of adequate BP control
is a major clinical issue because it is well established that
poor control of office BP during treatment predicts a high
risk of future cardiovascular disease (6–9) and that in-
treatment BP is more effective than pre-treatment BP for
cardiovascular risk stratification (7–9).
A growing body of evidence indicates that 24-h ambula-
tory BP (ABP) measurements are superior to office BP
measurements for cardiovascular risk stratification in sub-
jects with essential hypertension (10,11). However, prog-
nostic studies on 24-h ABP in hypertensive patients typi-
cally have been conducted in patients who were untreated at
the time of ABP monitoring. Therefore, the potential for
ABP to improve definition of individual risk in treated
hypertensive subjects remains unexplored. The aim of the
present study was to investigate the prognostic impact of BP
control over 24 h in a large cohort of subjects with essential
hypertension.
METHODS
The PIUMA study. The Progetto Ipertensione Umbria
Monitoraggio Ambulatoriale (PIUMA) study was estab-
lished in June 1986 as an observational registry in initially
untreated subjects with essential hypertension (12). Office
BP had to be 140 mm Hg systolic and/or 90 mm Hg
diastolic on at least three preliminary visits. Admission
criteria included absence of previous antihypertensive treat-
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ment or treatment having been withdrawn for at least four
weeks; no current or previous diagnosis of heart failure,
coronary artery disease, significant valvular defects, second-
ary causes of hypertension; 1 valid BP measurement per
hour over the 24 h. Patients with cancer or other important
pathologic conditions were excluded. Diabetes was not an
exclusion criterion. Diagnosis of diabetes included a fasting
glucose 7.77 mmol/l (140 mg/dl) or current treatment
with oral hypoglycemic drugs or insulin (13).
Blood pressure was measured by a physician with a
standard mercury sphygmomanometer in the outpatient
office in a quiet environment, on subjects seated and relaxed
for at least 10 min. The average of three measurements was
used for analysis. Ambulatory BP was recorded using an
oscillometric device (SpaceLabs 5200, 90202 and 90207,
SpaceLabs, Redmond, Washington), set to take a reading
every 15 min throughout the 24 h. The spontaneous
day-to-day variability of ABP was assessed in some of these
patients (14). Standard 12-lead electrocardiography (ECG)
was recorded in all subjects at 25 mm/s and 1 mV/cm
calibration. Left ventricular (LV) hypertrophy was tested
using a score recently developed in our laboratory (Perugia
score), which requires positivity of1 of the following three
criteria: SV3  RaVL 2.4 mV (men) or 2.0 mV
(women), left ventricular strain, a Romhilt-Estes score of
5 points (15,16). None of the subjects was treated with
digitalis.
Follow-up and assessment of end points. Follow-up was
mostly handled by patients’ family doctors, in cooperation
with the outpatient office of the referring hospital. Antihy-
pertensive management was driven by office BP values
recorded in the office. When PIUMA was established in
1986, most emphasis was given to diastolic BP control (90
mm Hg). In the subsequent years, systolic BP control was
increasingly pursued, as well, on the basis of emerging data
on treatment benefits in isolated systolic hypertension (17).
More recently, a BP target of 140 mm Hg systolic and 90
mm Hg diastolic has been endorsed. Although reports of
ABP monitoring were open to patients and their family
doctors, data were unlikely to affect therapeutic decisions
because they were considered investigational findings not
supported by operational guidelines. Also, the PIUMA
protocol states that therapeutic decisions should be based
on office BP measurements. Diuretics, -blockers,
angiotensin-converting enzyme (ACE) inhibitors, calcium
channel blockers and 1-blockers, alone or in various
combinations, were the antihypertensive drugs most fre-
quently used. Periodic contact with family doctors and
telephone interviews with patients were arranged to ascer-
tain the vital status and the occurrence of major cardiovas-
cular events.
The follow-up visit, which included standard laboratory
tests, 12-lead ECG and office and 24-h ABP measurement,
was undertaken after an average of 3.7 years (range 1 to 12)
of follow-up. Protocol for BP measurement and other
experimental procedures were the same as that in the
baseline study. Because the aim of the present study was the
assessment of subjects without previous cardiovascular
events both at entry and on the follow-up visit, those who
eventually developed an event before the follow-up visit
were excluded. At the end of the visit, ongoing antihyper-
tensive treatment was modified, if needed, according to the
degree of individual office BP control and overall cardiovas-
cular risk assessment.
Hospital record forms and other source documents of
patients who died or suffered a cardiovascular event months
or years after the follow-up visit were reviewed in conference
by the authors of this study. The international standard
criteria used to diagnose outcome events in the PIUMA
study have been described elsewhere (12,16). Cardiovascular
events included myocardial infarction, unstable angina with
concomitant ischemic ECG changes, coronary artery sur-
gery or angioplasty, sudden cardiac death, congestive heart
failure requiring hospitalization, stroke and transient isch-
emic attack. Transient ischemic attack was diagnosed by a
neurologist or internist in the presence of a rapid onset of a
focal neurological deficit, lasting more than 30 s and 24 h
and presumably due to ischemia. The PIUMA protocol
required that the deficit be present during the qualifying
clinical examination in order to be accepted and coded as a
terminating event. Patients with stroke were hospitalized
during the acute phase, and brain imaging and other
diagnostic tests were carried out according to individual
needs.
Data analysis. Statistical analysis was performed using
SPSS (SPSS Inc., Chicago, Illinois) and SAS-Stat (SAS
Institute, Cary, North Carolina). Parametric data are re-
ported as mean  standard deviation. For those subjects
who experienced multiple events, survival analysis was based
on the first event. Survival curves were calculated using
Kaplan-Meier product-limit method and compared by the
Mantel (log-rank) test. The effect of prognostic factors on
survival was assessed by stepwise Cox model (18). We first
tested a baseline model using the following variables: age
(y), gender (male, female), family history of premature (55
years in the father, 65 years in the mother) cardiovascular
disease (no, yes), diabetes (no, yes), LV hypertrophy at
ECG (no, yes), serum cholesterol (mmol/l), serum triglyc-
erides (mmol/l), smoking habits (nonsmokers, current
smokers), body mass index (kg/m2), antihypertensive treat-
ment at the follow-up visit (coded under four categories:
lifestyle measures alone, diuretics and -blockers alone or
Abbreviations and Acronyms
ABP  ambulatory blood pressure
ACE  angiotensin-converting enzyme
BP  blood pressure
ECG  electrocardiography
LV  left ventricular
PIUMA  Progetto Ipertensione Umbria Monitoraggio
Ambulatoriale
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combined, angiotensin-converting enzyme inhibitors and
calcium-antagonists alone or combined, other drug combi-
nations), time interval (weeks) between entry visit and
follow-up visit. Subsequent improvements in the model
fitting were tested by entering, one at a time, pre-treatment
and in-treatment BP values, either office or ambulatory.
Pulse pressure was calculated as systolic  diastolic BP. We
also tested a binary variable (yes, no) regarding office or
ABP control. Office BP control was defined by office values
140 mm Hg systolic and 90 mm Hg at the follow-up
visit. Ambulatory BP control was defined by an average
daytime ABP 135 mm Hg systolic and 85 mm Hg
diastolic (19) at the follow-up visit. In two-tailed tests, p
values 0.05 were considered statistically significant.
RESULTS
The baseline characteristics of the study population are
shown in Table 1. At entry, 74.9% of subjects had office
values of both systolic and diastolic BP 140 and 90 mm
Hg, respectively; 10.6% of subjects had isolated systolic
hypertension and the remaining 14.4% had isolated diastolic
hypertension. Features of subjects with and without subse-
quent cardiovascular disease events are also reported in the
table. At the follow-up visit, 210 out of 790 subjects (26.6%)
achieved adequate control of office BP; 295 subjects (37.3%)
achieved control of ABP. Overall, 32% of the subjects were
using lifestyle measures alone and 68% were being treated
with antihypertensive drugs. Of these, 268 received mono-
therapy with diuretics (n  19), -blockers (n  50), ACE
inhibitors (n 100) or angiotensin II antagonists (n  17),
calcium channel blockers (n  64) or other drugs (n  18).
The remaining subjects were treated with various drug
combinations, mostly ACE inhibitors plus diuretics. Office
BP and 24-h ABP at the entry visit and at follow-up visit
are reported in Figure 1. From the baseline to the follow-up
visit, office BP decreased from 156/98 mm Hg to 145/91
mm Hg, and 24-h ABP from 137/87 mm Hg to 128/81
mm Hg (all p  0.01). At the follow-up visit, systolic BP
was higher in the subset with subsequent cardiovascular
events than in that without events (office systolic BP: 150 vs.
145 mm Hg, 24-h systolic BP: 135 vs. 127 mm Hg; both
p  0.05). Diastolic BP did not differ significantly between
the two groups (90 vs. 90 mm Hg; 84 vs. 81 mm Hg). Pulse
pressure was higher in the subset with subsequent cardio-
vascular events than in that without events (office pulse
pressure: 59 vs. 54 mm Hg; 24-h pulse pressure: 51 vs. 46
mm Hg, both p  0.05).
Outcome events. Subsequently to the follow-up visit, 58
subjects developed a first cardiovascular event. There were
14 subjects with myocardial infarction, 13 with new-onset
angina and ST segment changes (2 of whom underwent
coronary bypass surgery), 2 with heart failure requiring
hospitalization, 15 with stroke and 8 with transient ischemic
attack, 2 with occlusive arterial vascular disease and 4 with
renal failure requiring dialysis. Event rate was 0.71  100
patient-years in the subset who had achieved ABP control
(11 events out of 295 patients) versus 1.87 in the subset with
higher ABP (47 events out of 495 patients) (p  0.0026).
Figure 2 shows the incidence of cardiovascular events in
treated hypertensive subjects with and without adequate
control of ambulatory blood pressure. Office BP control was
associated with a nonsignificant lesser risk of subsequent
cardiovascular events (0.98 vs. 1.16 events  100 patient-
years; p  0.12).
Multivariate analysis. Results are reported in Table 2.
After controlling for age, diabetes and LV hypertrophy by
ECG, achieved ABP control independently predicted a
considerably lesser risk for subsequent cardiovascular events
(relative risk 0.36; 95% confidence intervals: 0.18 to 0.70;
p  0.003). In contrast, office BP control did not achieve
significance (relative risk 0.63; 95% confidence intervals:
0.31 to 1.31; p  NS). When both office and ABP control
were forced in the same model, only ABP control achieved
significance (p  0.003). In-treatment systolic (p  0.003)
Table 1. Main Characteristics in the Total Population and in
the Subsets With and Without Cardiovascular Events Over










Age (yrs) 51 (12) 48 (11) 54 (9)*
Body mass index (kg/m2) 26.7 26.6 (3.8) 27.3 (3.4)
Gender (% men) 56.7 55.7 69.0*
Diabetes (%) 4.8 3.8 17.2*
Cigarette smoking (%) 25.2 24.3 36.2*
Office systolic BP (mm Hg) 156 (18) 155 (18) 161 (18)**
Office diastolic BP (mm Hg) 98 (9) 98 (9) 97 (11)
Office pulse pressure (mm Hg) 57 (17) 56 (16) 64 (19)*
Office HR (beats/min) 74 (10) 75 (10) 72 (10)
24-h systolic BP (mm Hg) 137 (14) 137 (15) 143 (15)*
24-h diastolic BP (mm Hg) 87 (10) 87 (10) 89 (11)
24-h pulse pressure (mm Hg) 49 (9) 49 (9) 54 (11)*
24-h HR (beats/min) 75 (9) 75 (9) 73 (10)
Daytime systolic BP (mm Hg) 142 (14) 142 (14) 148 (15)*
Daytime diastolic BP (mm Hg) 92 (10) 92 (10) 94 (11)
Daytime PP (mm Hg) 50 (9) 49 (9) 54 (11)*
Daytime HR (beats/min) 79 (10) 79 (9) 77 (10)
Nighttime systolic BP
(mm Hg)
126 (15) 126 (15) 131 (17)*
Nighttime diastolic BP
(mm Hg)
78 (11) 77 (11) 79 (12)
Nighttime PP (mm Hg) 49 (9) 48 (9) 52 (11)*
Nighttime HR (beats/min) 68 (9) 68 (9) 67 (10)
Glucose (mmol/l) 5.55 (1.1) 5.50 (1.1) 6.19 (1.4)*
Creatinine (mol/l) 86.9 (19) 86.3 (19) 93.4 (28)*
Total cholesterol (mmol/l) 5.54 (1.1) 5.53 (1.1) 5.61 (1.0)
HDL cholesterol (mmol/l) 1.25 (0.30) 1.27 (0.30) 1.10 (0.27)*
LDL cholesterol (mmol/l) 3.54 (0.93) 3.53 (0.93) 3.71 (0.95)
Triglycerides (mmol/l) 1.65 (1.10) 1.63 (1.11) 1.92 (0.97)*
Uric acid (mmol/l) 0.281 (0.08) 0.279 (0.08) 0.313 (0.08)*
Potassium (mmol/l) 4.17 (0.38) 4.16 (0.36) 4.27 (0.52)*
LV hypertrophy (%) 17.0 15.7 33.3*
Data expressed as mean ( standard deviation).
*p  0.01; **p  0.05.
BP blood pressure; PP pulse pressure; HR heart rate; HDL high density
lipoprotein; LDL  low density lipoprotein; LV  left ventricular.
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and diastolic (p  0.006) ABP levels were also independent
predictors of subsequent events; office BP levels were not (all
p  NS). For every 12-mm Hg (1 SD) increase in 24-h
systolic BP at the follow-up visit, there was an independent
49% increase in the risk of future cardiovascular events, and
for every 8-mm Hg (1 SD) increase in 24-h diastolic BP,
there was an independent 47% increase of events. None of
the other tested variables (see data analysis) achieved statis-
tical significance. Pre-treatment 24-h pulse pressure
achieved significance (p  0.026); pre-treatment 24-h
systolic BP bordered significance (p  0.07).
Figure 3 shows the progressive rise in the age-adjusted
five-year risk of cardiovascular disease from the bottom to
the top quartile of in-treatment 24-h ABP, according to the
presence or absence of diabetes and LV hypertrophy.
Division points for quartiles are 120, 127 and 134 mm Hg
for 24-h systolic BP and 75, 81 and 86 mm Hg for 24-h
diastolic BP. The age- and risk-factor adjusted increase in
cardiovascular disease risk with progressively higher values
of pre-treatment and in-treatment ABP is shown in Figure
4. For any given increment in 24-h ABP, the age- and
risk-factor adjusted five-year event risk increased in a
steeper fashion with in-treatment than with pre-treatment
levels, both systolic and diastolic.
DISCUSSION
The present study increases our understanding of the
prognostic value of ABP in treated hypertensive subjects by
showing that ABP achieved during treatment is a more
Figure 1. Office and 24-h ambulatory blood pressure at entry (black bars) and follow-up (white bars).
Figure 2. Incidence of cardiovascular (CV) disease in treated hypertensive subjects with and without adequate control of ambulatory blood pressure (ABP).
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potent determinant of the risk of cardiovascular disease than
achieved office BP.
Previous studies with ABP. The prognostic value of ABP
has been previously tested in several event-based studies in
subjects who were untreated at the time of execution of
ABP monitoring (12,20–23). However, although those
studies provide strong evidence of the clinical value of this
diagnostic technology for cardiovascular risk stratification in
untreated hypertensive subjects (12,20–23), their applica-
bility to treated subjects remains unproved. Only a few,
small longitudinal studies with ABP monitoring have been
carried out in treated hypertensive populations. In one of
these studies (24), 86 patients with poorly controlled hyper-
tension under drug treatment were followed for 4 years, and
during this period 21 patients suffered a first cardiovascular
event. Event rate was higher (p  0.02) in the upper (13.6
events/100 patient-years) than in the middle (9.5 events/
100 patient-years) and lowest (2.2 events/100 patient-years)
Table 2. Results of the Multivariate Analysis
Variable Increment
Relative Risk
(95% Confidence Intervals) p Value
Baseline model
Age 10 years 1.41 (1.07–1.85) 0.011
Diabetes Yes vs. no 3.38 (1.66–6.91) 0.008
LV hypertrophy Yes vs. no 2.16 (1.22–3.80) 0.008
Full model
Office BP control* Yes vs. no 0.64 (0.31–1.31) NS
Ambulatory BP control** Yes vs. no 0.36 (0.18–0.70) 0.003
Pre-treatment office SBP 1 SD (18 mm Hg) 1.07 (0.81–1.42) NS
Pre-treatment office DBP 1 SD (9 mm Hg) 0.92 (0.72–1.18) NS
Pre-treatment office PP 1 SD (17 mm Hg) 1.16 (0.86–1.57) NS
Pre-treatment 24-h SBP 1 SD (14 mm Hg) 1.27 (1.00–1.91) NS
Pre-tretament 24-h DBP 1 SD (10 mm Hg) 1.05 (0.78–1.41) NS
Pre-treatment 24-h PP 1 SD (9 mm Hg) 1.31 (1.04–1.65) 0.026
In-treatment office SBP 1 SD (16 mm Hg) 1.07 (0.83–1.37) NS
In-treatment office DBP 1 SD (9 mm Hg) 1.09 (0.86–1.40) NS
In-treatment office PP 1 SD (14 mm Hg) 1.01 (0.77–1.33) NS
In-treatment 24-h SBP 1 SD (12 mmHg) 1.49 (1.14–1.92) 0.003
In-treatment 24-h DBP 1 SD (8 mm Hg) 1.47 (1.12–1.92) 0.006
In-treatment 24-h PP 1 SD (8 mm Hg) 1.21 (0.94–1.56) NS
The different blood pressure components were added one at a time to the baseline model, and the associated relative risk is
adjusted for the baseline model.
*Office BP  140 mm Hg systolic and 90 mm Hg diastolic; **Average daytime ambulatory BP  135 mm Hg systolic and
85 mm Hg diastolic (17).
BP  blood pressure; SBP  systolic blood pressure; DBP  diastolic blood pressure; PP  pulse pressure; SD  standard
deviation.
Figure 3. Age-adjusted (Cox model) five-year risk of cardiovascular (CV) disease at different levels of 24-h in-treatment systolic and diastolic blood pressure
(BP), diabetes and left ventricular (LV) hypertrophy. The calculated risk corresponds to the median within each quartile.
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tertiles of daytime diastolic BP. This study was the first to
suggest the prognostic value of ABP in treated patients with
resistant hypertension, but results cannot be extended to a
general population of treated hypertensive subjects with
variable degrees of BP control. A cohort study in 116
treated hypertensive subjects followed for 31 months con-
firmed the prognostic value of ABP, but results are limited
by the small sample size (25). A longitudinal general
population study from Japan (26), a study in patients with
symptomatic lacunar infarcts (27) and a study in patients
with type II diabetes (28) provided additional evidence of
the prognostic value of ABP. However, because those
studies included both treated and untreated subjects and
were performed in a variety of clinical settings, results
cannot be reliably extended to the specific context of treated
subjects with essential hypertension.
Role of BP control. There is ample evidence from previous
studies that achieved BP is an important predictor of
cardiovascular risk in treated hypertensive subjects (6–9). In
the International Prospective Primary Prevention Study in
Hypertension (7), for every 5-mm Hg reduction in diastolic
BP from before to during treatment, there was an indepen-
dent 24% reduction of cardiac events and a 63% reduction in
cerebrovascular events. In that study, pre-treatment BP was
not a statistically significant predictor of outcome (7). In the
Glasgow Blood Pressure Clinic, long-term mortality rate in
3,783 treated hypertensive subjects was directly associated
with the BP reduction induced by treatment, even after
controlling for age, gender and pre-treatment BP (8). In the
Department of Health and Social Security Hypertension
Care Computing Project, long-term mortality rate in 2,855
hypertensive subjects was not predicted by pre-treatment
BP; it was by in-treatment BP (9). In our study, the
proportion of subjects who achieved an adequate control of
office BP, defined by a sphygmomanometric BP 140 mm
Hg systolic and 90 mm Hg diastolic, was 26.6%, in
agreement with a 28% control rate in a previous survey from
northern Italy (4). Subjects with adequate control of their
office BP showed a 36% lesser risk of future cardiovascular
events compared with those with higher BP, but such
reduction was not statistically significant because of the wide
confidence intervals, possibly due to the limited sample size.
However, the subjects with adequate control of ABP,
defined by an achieved daytime ABP 135 mm Hg systolic
and 85 mm Hg diastolic (19), showed a 64% reduction
(95% confidence interval 30% to 82%) in the risk of future
cardiovascular events when compared with subjects with
higher ABP levels. Furthermore, in-treatment ABP, but
not pre-treatment ABP or pre-treatment or in-treatment
office BP, independently predicted the subsequent occur-
rence of adverse cardiovascular events.
These data provide substantial evidence that achieved
ABP is a potent determinant of subsequent outcome and
that its potency is superior to that of pre-treatment ABP
and that of pre-treatment or in-treatment office BP. The
higher prevalence of ABP control when compared with
office BP control (26.6 vs. 37.3; p  0.001) could be
ascribed to the persistence of a white-coat effect even during
the follow-up visit, as demonstrated by Parati et al. (29).
However, the definition of “adequate” ABP control could
also play a role. In this study, adequate ABP control was
defined by an average daytime ABP 135 mm Hg systolic
and 85 mm Hg diastolic, as suggested by an ad hoc panel
of the American Society of Hypertension (19). The preva-
lence of subjects with adequate ABP control defined by
using lower or higher limits may be expected to decrease or
increase, respectively. For example, when using a cut-off
value for 24-h ABP normality of 123/77 mm Hg (4),
prevalence of our subjects with ABP control was 19.6%.
Study limitations. Because the PIUMA study sample in-
cludes only Caucasian subjects, caution is needed in extrap-
olating our results to different ethnic groups. Another
limitation, which applies to all the observational cohort
studies, is the lack of control for occasional changes in the
Figure 4. Age- and risk-factor adjusted five-year risk of cardiovascular (CV) disease with increasing pre-treatment and in-treatment average 24-h blood
pressure (BP).
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antihypertensive regimen over time. The planned exclusion
of subjects with cardiovascular events before the follow-up
visit including an ABP monitoring could have been a
potential source of selection of our sample. Finally, we relied
on a single follow-up visit to estimate the degree of BP
control over the entire follow-up period.
Implications. Our findings do not imply that 24-h ABP
monitoring should be used routinely in all treated subjects
with essential hypertension. The Joint National Committee
VI (30), the World Health Organization/International So-
ciety of Hypertension Committee (31) and the British
Hypertension Society (32) provided a list of clinical condi-
tions in which ABP monitoring might be clinically useful.
These conditions may be grouped under all four areas of
suspected white-coat hypertension, excessive BP variability
over the same or different clinical visits, symptoms suggest-
ing hypotensive episodes in the presence or absence of
antihypertensive treatment; apparent resistance to multiple
drug treatment (30–32). Yet the present study and growing
numbers of other surveys are providing evidence that ABP
is more potent than sphygmomanometric BP for cardiovas-
cular risk stratification in both treated and untreated sub-
jects with essential hypertension (10,11). The stage is now
set for intervention trials aimed to establish whether a
management of hypertension based on results of ABP is
superior, in terms of prevention of organ damage or cardio-
vascular events, to a traditional management based on office
BP. In a recent study, adjustment of antihypertensive
treatment based on ABP values instead of office BP values
led to a less intensive drug treatment with comparable
effects on BP control and left ventricular mass (33). Inter-
vention trials should also include assessment of the prog-
nostic value of self-measured home BP, which was not
possible in the context of the present study.
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